



2019 HIV & HBV Cure Forum

20 & 21 July 2019

Mexico City, Mexico

SATURDAY 20 JULY 2019

8h00 – 9h00		Registration
9h00 – 10h00	Opening Session	Welcome and Introduction Sharon Lewin, The Doherty Institute, The University of Melbourne, Australia Anna Kramvis, University of the Witwatersrand, South Africa Chair Steve Deeks, UCSF, United States Keynote Hepatitis B virus: an ancient curse and the modern blessing for its cure Jake Liang, NIH Intramural Research Program, United States
10h00 – 11h20	Session 1	Biomarkers of cure: Understanding persistence Co-chairs Éric Cohen, Institut de Recherches Cliniques de Montréal, Canada Eileen Scully, Johns Hopkins University, United States Invited speakers Measuring the HIV reservoir: Insights from single cell analyses Lillian Cohn, Chan Zuckerberg Biohub, United States HBV cure therapies: How do we measure success? John Tavis, Saint Louis University School of Medicine, United States OA1-1 Clonal integration site expansion of infected cells is a main contributor of HIV persistence in more differentiated T cell subsets during suppressive ART <i>Jori Symons, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Australia</i> OA1-2 Longitudinal proviral sequencing provides a window into selection pressures exerted on infected cells and provides an upper bound estimate of proviral half-lives which are influenced by expression and splicing potential <i>Una O'Doherty, University of Pennsylvania, United States</i>

OA1-3 Immune activation markers associated with levels and diversity of intact HIV proviruses during HIV-HBV co-infection
Ciccy Xiao Qian Wang, The Westmead Institute for Medical Research and Sydney Medical School-Westmead, University of Sydney, Australia

General Discussion 10'

11h20 –
11h50

Break

11h50 –
12h50

Session 2 **Role of Antivirals in Cure**

Co-chairs Monique Nijhuis, University Medical Center Utrecht, Netherlands
Joe Sasadeusz, Alfred Hospital, Australia

Invited Speakers **Why think about antiretrovirals and eradication of HIV?**
Daria Hazuda, Merck & Inc., United States

Can HBV be cured by antiviral therapy alone?
Massimo Levrero, Hepato-Gastroenterology, Hospice Civils de Lyon and INSERM U1052 – Cancer Research Center of Lyon (CRCL), France

Flash talk **Effects of siRNA on hepatitis B virus infection**
Man Fung Yuen, The University of Hong Kong, Hong Kong

General Discussion 10'

12h50 –
14h00

Lunch

14h00 –
14h50

Session 3 **Gene Therapy**

Co-chairs Keith Jerome, Fred Hutchinson Cancer Research Center, United States
Anna Kramvis, University of the Witwatersrand, South Africa

Invited Speakers **Status and update of HIV gene therapy clinical trials**
Pablo Tebas, Perelman School of Medicine, University of Pennsylvania, United States

The prospects of curing chronic HBV infection using gene therapy
Patrick Arbuthnot, University of the Witwatersrand, South Africa

General Discussion 10'

	Flash talk	<p>Multiscale imaging of therapeutic antibody distribution and localization Thomas J. Hope, Feinberg School of Medicine, Northwestern University, United States</p> <p>General Discussion 10'</p>
10h20 – 10h50		Break
10h50 – 12h10	Session 6	Immunotherapy: Immune-Modifying Agents
	Co-chairs	Michaela Müller-Trutwin, Institut Pasteur, France Mirko Paiardini, Emory University, United States
	Invited Speakers	<p>Engineered immune-mobilising monoclonal T cell receptors against viruses Lucy Dorrell, University of Oxford, United Kingdom</p> <p>Immunomodulatory approaches for HBV cure Abhishek Garg, Gilead Sciences, United States</p>
	OA6-1	Targeting HIV/SIV Infection of CD4+ T Follicular Helper (Tfh) Cells: BCL6 Inhibition Represses HIV Infection CD4+ T Cells and Reduces Germinal Center Hyperplasia in Rhesus Macaque <i>Yanhui Cai, The Wistar Institute, United States</i>
	OA6-2	Fingolimod treatment at ART initiation delays SIV rebound after ART interruption <i>Maria Pino, Yerkes National Primate Research Center, Emory University, United States</i>
	OA6-3	Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals <i>Sharon Riddler, University of Pittsburgh School of Medicine, United States</i>
		General Discussion 10'
12h10 – 12h40	Closing Session	Closing Lecture
	Chair	Anna Kramvis, University of the Witwatersrand, South Africa
		Disruptive discoveries for HBV treatment and eradication Raymond Schinazi, Emory University School of Medicine, United States
12h40 – 12h50		IAS/Abivax Research-for-Cure Academy Fellowship Prize

12h50 – 13h05	Highlights and next steps from the Sunnylands Summit: The Path Towards Ending HIV Sharon Lewin, The Doherty Institute, The University of Melbourne, Australia
13h05 – 13h20	Closing Remarks Steve Deeks, UCSF, United States